IL161155D0 - Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors - Google Patents

Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors

Info

Publication number
IL161155D0
IL161155D0 IL16115502A IL16115502A IL161155D0 IL 161155 D0 IL161155 D0 IL 161155D0 IL 16115502 A IL16115502 A IL 16115502A IL 16115502 A IL16115502 A IL 16115502A IL 161155 D0 IL161155 D0 IL 161155D0
Authority
IL
Israel
Prior art keywords
diabetes
treatment
type
insulin resistance
resistance syndrome
Prior art date
Application number
IL16115502A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33698101P priority Critical
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to PCT/IB2002/003754 priority patent/WO2003037432A1/en
Publication of IL161155D0 publication Critical patent/IL161155D0/en

Links

IL16115502A 2001-11-02 2002-09-12 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors IL161155D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33698101P true 2001-11-02 2001-11-02
PCT/IB2002/003754 WO2003037432A1 (en) 2001-11-02 2002-09-12 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors

Publications (1)

Publication Number Publication Date
IL161155D0 true IL161155D0 (en) 2004-08-31

Family

ID=23318571

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16115502A IL161155D0 (en) 2001-11-02 2002-09-12 Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors

Country Status (13)

Country Link
US (2) US6967204B2 (en)
EP (1) EP1444009A1 (en)
JP (1) JP2005508978A (en)
KR (1) KR20040053210A (en)
CN (1) CN1575191A (en)
BR (1) BR0213817A (en)
CA (1) CA2465632A1 (en)
HU (1) HU0401998A2 (en)
IL (1) IL161155D0 (en)
MX (1) MXPA04004170A (en)
PL (1) PL370599A1 (en)
WO (1) WO2003037432A1 (en)
ZA (1) ZA200402173B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
KR20040053210A (en) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
EP1481077B1 (en) * 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
AT352312T (en) * 2001-12-29 2007-02-15 Novo Nordisk As Combined use of a glp-1 compound and an aldose reductase inhibitor
IS1935B (en) * 2002-03-19 2004-06-16 Actavis Group Hf. Fosinopril drug combination
AT478872T (en) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, process for their preparation and therapeutic application
DE10238723A1 (en) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituted Pyrazolyprimidine
DE10238722A1 (en) * 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE10238724A1 (en) * 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
DE102004004142A1 (en) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
WO2004099211A1 (en) * 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (en) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-arylmethyl-substituted pyrazolopyrimidines
BRPI0416118A (en) * 2003-10-31 2007-01-02 Pfizer Prod Inc phosphodiesterase 9 inhibition as a treatment for obesity-related conditions
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US8673964B2 (en) 2004-05-20 2014-03-18 Diamedica Inc. Use of drug combinations for treating insulin resistance
ES2526701T3 (en) 2005-06-14 2015-01-14 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivative
WO2007025103A2 (en) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
CN101501007B (en) 2006-08-08 2014-01-29 Aska制药株式会社 Quinazoline derivative
CA2662084A1 (en) 2006-09-07 2008-03-13 Nycomed Gmbh Combination treatment for diabetes mellitus
WO2008036678A2 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
EP2123301A4 (en) * 2006-12-13 2010-11-03 Aska Pharm Co Ltd Therapeutic agent for urinary tract disease
ITMI20070140A1 (en) * 2007-01-30 2008-07-31 Campagnolo Srl Device interaction man-bicycle
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
NZ580904A (en) * 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
MX2009013354A (en) 2007-06-04 2010-07-06 Univ Ben Gurion Tri-aryl compounds and compositions comprising the same.
CA2706018C (en) 2007-11-30 2015-11-24 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
EP3199203A1 (en) 2008-02-29 2017-08-02 Concert Pharmaceuticals Inc. Substitued xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
AP201105819A0 (en) 2009-03-31 2011-08-31 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydropyrazolo[3,4-D] pyrimidin -4-one derivatives and their use as PDE9A modulators.
KR101623762B1 (en) 2008-04-02 2016-05-24 베링거 인겔하임 인터내셔날 게엠베하 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
AU2009289240A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of CNS disorders
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TWI404721B (en) 2009-01-26 2013-08-11 Pfizer Amino-heterocyclic compounds
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
AR078793A1 (en) 2009-10-27 2011-12-07 Orion Corp Nonsteroidal derivatives and carboxamides acyl hydrazone of androgen receptor modulators selective tissue (SARM), pharmaceutical compositions containing them and use thereof in the treatment of prostate cancer among other
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
GEP20146217B (en) 2010-08-12 2015-01-12 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
EA023493B1 (en) 2010-09-07 2016-06-30 Астеллас Фарма Инк. Pyrazoloquinoline compound
US20120157458A1 (en) * 2010-09-20 2012-06-21 Amy Ripka Imidazotriazinone compounds
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
KR20150075120A (en) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP3121178B1 (en) 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor
SG11201403909RA (en) 2012-01-26 2014-10-30 Lundbeck & Co As H Pde9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc Imidazotriazinone compounds
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
LT2854841T (en) 2012-06-04 2017-06-12 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
BR112015002080A2 (en) 2012-08-02 2017-07-04 Merck Sharp & Dohme compound, pharmaceutical composition, use of a compound, and method of treating or preventing a disorder, condition or disease
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
CN102786525B (en) 2012-08-08 2014-12-17 中山大学 N-substituted pyrazolo [3, 4-d] pyrimidine ketone compound and preparation method and application thereof
JP2015067538A (en) * 2013-09-26 2015-04-13 株式会社アイエイアイ Hypoglycemic agent
MX2016005995A (en) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compounds for the treatment of diabetes and disease complications arising from same.
CA2981791A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
EA201990665A1 (en) 2016-09-09 2019-08-30 Инсайт Корпорейшн Hpk1 regulators based on pyrazolopyridine derivatives and their application for treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
DE19541264A1 (en) 1995-11-06 1997-05-07 Bayer Ag Purin-6-one derivatives
AU722514B2 (en) * 1995-12-28 2000-08-03 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9722520D0 (en) * 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6444816B1 (en) * 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
EP1146888A2 (en) 1998-10-15 2001-10-24 BioImage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targetting
HU0300725A3 (en) * 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
BR0206847A (en) * 2001-02-02 2004-02-25 Pfizer Treatment of diabetes mellitus
AUPR576801A0 (en) 2001-06-19 2001-07-12 University Of Tasmania Methods and pharmaceuticals for treating muscle insulin resistance and related conditions
KR20040053210A (en) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease

Also Published As

Publication number Publication date
EP1444009A1 (en) 2004-08-11
CN1575191A (en) 2005-02-02
PL370599A1 (en) 2005-05-30
US20040023989A1 (en) 2004-02-05
WO2003037432A1 (en) 2003-05-08
US20050070557A1 (en) 2005-03-31
MXPA04004170A (en) 2004-09-06
KR20040053210A (en) 2004-06-23
JP2005508978A (en) 2005-04-07
US6967204B2 (en) 2005-11-22
CA2465632A1 (en) 2003-05-08
ZA200402173B (en) 2005-03-18
HU0401998A2 (en) 2005-01-28
BR0213817A (en) 2004-10-19

Similar Documents

Publication Publication Date Title
DE60210961D1 (en) Catheter with low resistance
DK1240325T3 (en) IL-17 and IL-17R homologous polypeptides and therapeutic use thereof
DE60317663D1 (en) Fluorchemical composition containing a fluorinated polyethere and its use in the treatment of fiber materials
DE60212048D1 (en) Catheter with improved distal pushing ability
DE60134134D1 (en) Prophylactic and therapeutic treatment of ten with compounds based on monosaccharides
DE60332019D1 (en) Catheter and intake needle arrangement with needle protection
DK1427758T3 (en) Preparations and Methods for Treating Diabetes
DE60128475D1 (en) N-substituted indole used in the treatment of diabetes
DE60225719D1 (en) Cis-2,4,5-triphenyl-imidazoline and its use in the treatment of tumors
DE60329287D1 (en) Boehmitteilchen and these polymermaterials containing
DE50214903D1 (en) Zinc free and zinc arm insulin preparations with improved stability
DE50009607D1 (en) Substituted oxazolidinone and its use in the field of blood
DE60238638D1 (en) Catheter with improved connection between balloon and catheter
DE60222394D1 (en) Implantable medical device with possibility for temperature measurement and storage
TW576128B (en) Electrooptic device and manufacturing method of the same, and electronic device
DE60208351D1 (en) Glucopyranosyloxybenzylbenzole derivatives and their medical use
DE60230591D1 (en) Glycopyranosyloxypyrazole derivatives and their medical use
GB2344526B (en) Syringe with filter,and filter therefor
DE60237580D1 (en) Glycopyranosyloxypyrazole derivatives and their medical use
DK0996444T3 (en) Treatment of diabetes with thiazolidinedione and metformin
DE50202634D1 (en) Stabilized mrna with increased g / c content and optimized codon usage for gene therapy
DE60237733D1 (en) Device with operating mode and sleep mode
DE60321929D1 (en) Pharmaceutical compositions with dextromethorphane and chinidine for the treatment of neurological illnesses
DE60239612D1 (en) Monodisperse mixtures and method for the treatment of diabetes
DE60324194D1 (en) Catheter with several infusion sections and related methods